TLX
Telix Shines in H1 2026 Results: Precision Medicine Business Booms, Regulatory Progress Made
The Australian-based radiopharmaceutical company Telix has announced its half-year results for 2026, showcasing significant growth and progress across various fronts. In a presentation to investors, Telix's Managing Director and Group CEO, Dr. Christian Behrenbruch, highlighted the company's competitive advantages and strategic priorities for the year. Dr.